September 30, 2024 by Nicole Silbermann, Helmholtz Association of German Research Centres So-called high-dose flu vaccines are available for older people. The reason: their immune system does not always respond sufficiently well to the standard flu vaccines. Why this is the case and the molecular processes behind it are not yet understood. However, in their...
Category: <span>Pharmaceutical Updates</span>
Post
Regulating iron overload: Liraglutide’s potential benefits
By Dr. Priyom Bose, Ph.D.Reviewed by Benedette Cuffari, M.Sc. Study: Liraglutide Impacts Iron Homeostasis in a Murine Model of Hereditary Hemochromatosis. Image Credit: Peter Togel / Shutterstock.com A recent Endocrinology study assesses the role of liraglutide in regulating iron metabolism in a mouse model of hereditary hemochromatosis, diet-induced obesity, and glucose intolerance. Treatment options for...
Post
Commonly used drug could transform treatment of rare muscle disorder
September 27, 2024 by University College London Lamotrigine, a drug commonly used to treat epilepsy and certain mood disorders, has been shown to be an excellent treatment option for a rare genetic neuromuscular disease known as non-dystrophic myotonia, in a world-first trial led by University College London researchers. The study, published in The Lancet Neurology,...
Post
Two studies find SARS-CoV-2 virus becoming resistant to antiviral drugs used to treat patients
September 27, 2024 by Bob Yirka , Medical Xpress Two studies have found that the virus that causes COVID-19 is becoming resistant to two drugs used to treat patients with infections. In the first study, a combined team from Cornell University and the National Institutes of Health studied the treatment outcomes for patients with compromised...
Post
Synthetic compound shows promise against drug-sensitive, drug-resistant strains of human malaria parasites
September 26, 2024 by University of California – Riverside This photomicrograph of a blood smear contains a macro- and microgametocyte of the Plasmodium falciparum parasite. In 2022, nearly 619,000 global deaths due to malaria were caused by Plasmodium falciparum, the most virulent, prevalent, and deadly human malaria parasite. For decades, the parasite’s resistance to all...
Post
Tirzepatide Leads to Long-Term Glucose Control
Medscape Medical News > Conference News > EASD 2024 Nancy A. Melville September 25, 2024 MADRID — The majority of patients achieving high rates of glucose control and weight loss in the first year of tirzepatide treatment have sustained success in the second year; however, factors predicting a sustained response are less clear for weight...
Post
Blueberry-derived compound shows promise in enhancing colonic mucosal barrier function
September 25, 2024 by Maximum Academic Press Effect of M3G on the pathological morphology of colon tissue. (a) HE staining of colon tissue. Original magnifications: 100×. (b) PAS staining of colon tissue. Original magnifications: 100×. (c) The damage score of colon tissue. (1) Epithelial cell damage: 0 = normal morphology; 1 = regional destruction of...
Post
AI model identifies existing drugs that can be repurposed for treatment of rare diseases
September 25, 2024 by Harvard Medical School There are more than 7,000 rare and undiagnosed diseases globally. Although each condition occurs in a small number of individuals, collectively these diseases exert a staggering human and economic toll because they affect some 300 million people worldwide. Yet, with a mere 5 to 7% of these conditions...
Post
Promising drug combo targets aggressive bladder cancers
September 25, 2024 by Columbia University Tumors in a section of untreated muscle invasive bladder cancer (left) vs. section treated with Rosiglitazone and Trametinib showing 91% fewer tumors (right). Credit: Columbia UniversityA new study in mice by researchers at the Herbert Irving Comprehensive Cancer Center (HICCC) has identified a promising drug combination for the treatment...
Post
Psilocybin Bests SSRI for Major Depression in First Long-Term Comparison
Medscape Medical News > Conference News > ECNP 2024 Kate Johnson September 23, 2024 MILAN — Psilocybin leads to a better overall outcome in the treatment of moderate to severe major depressive disorder (MDD) than the selective serotonin reuptake inhibitor (SSRI) escitalopram, results of the first long-term comparison of the two treatments suggest. “This is...